ClinicalTrials.gg
CompletedNCT05983939Updated Feb 14, 2024

Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of PIPE-791 and Food Effect in Healthy Volunteers

A Phase 1 interventional study of PIPE-791 and Placebo in Multiple Sclerosis, sponsored by Contineum Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-14.

Sponsored by Contineum Therapeutics · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Feb 2024, 2 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,192 studies in Multiple Sclerosis with a site in United States — 184 open to participants now, 259 under way, 23 of them phase 3. Multiple Sclerosis · United States.

Enrollment
404th of 879
56 · median 50
Started
2023
with 68 others
Phase 1
105 of 1,192
18 open now
Registered
1,002nd of 1,192
by date

Among the 1,192 studies in Multiple Sclerosis with a site in United States, this one is the 404th largest by enrollment of the 879 interventional ones that give a count, is one of 69 that started in 2023, is one of 105 in phase 1, and was the 1,002nd registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

184 of the 1,192 studies in Multiple Sclerosis with a site in United States are open now. Recruiting first, the newest first:

179 more — sign in →

All 184 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,192 studies in Multiple Sclerosis with a site in United States, or all of them as a file.
02

Study summary

This study will be conducted in three parts: Part 1 will be a Single Ascending Dose (SAD), Part 2 will be a Multiple Ascending Dose (MAD), and Part 3 will be a selected SAD cohort in a fed state. Safety will be assessed by periodic measurement of vital signs, physical examinations, electrocardiograms, blood laboratory analyses and occurrence of adverse events (AE).

Read the detailed description

This is a randomized, double-blind study of PIPE-791 or placebo given as single and multiple escalating doses in normal healthy subjects. The study will be conducted in three parts: Part 1 will be a Single Ascending Dose (SAD) study enrolling approximately 48 subjects for a total duration of 6 weeks. Part 2 will be a Multiple Ascending Dose (MAD) study enrolling approximately 32 subjects for a total duration of 7 weeks, and part 3 will be a selected SAD cohort in a fed state to evaluate the effect of food on the bioavailability of PIPE-791, enrolling approximately 8 subjects for a duration of 6 weeks.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

Keywords

  • Multiple Sclerosis
  • PIPE-791
  • Health volunteers
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female between 18 and 55 years of age (inclusive) at the time of signing .
  • Male or female subjects with agree to comply with protocol-approved double barrier method 30 days prior to the first dose and up to 90 days post last dose.
  • Medically healthy with no or relevant abnormalities in medical history, physical exam, vital signs, (ECG), or laboratory evaluations (hematology, chemistry, and urinalysis) as assessed by the Investigatory.

Exclusion criteria

Exclusion Criteria:

  • Has a current or recurrent disease that could affect the medicinal product or affect clinical or laboratory assessments.
  • Experienced a significant systemic illness, as judged by the Investigator, within 30 days of the first dose.
  • Has a history of a significant medical, including hepatic and/or renal disease as outlined in the protocol, or psychiatric disorder that may require treatment or make the participant unlikely to fully complete the study or increase risk to the participant.
  • History of alcohol or other substance abuse within the 12 months prior to the dosing at the discretion of the Investigator.
  • Routine alcohol consumption meeting or exceeding protocol limits.
  • History of prior (except adequately treated non-melanoma skin cancer, carcinoma in-situ of the uterine cervix, ductal carcinoma in situ (DCIS), or localized prostate cancer).
  • Donated or lost more than 400 mL of blood within 56 days or plasma within 14 days prior to Screening.
  • Received an investigational agent within the last 30 days, prior to screening, or five half-lives of the prior investigational agent.
  • Use of any prescription medication, over-the-counter medication, vitamin or supplement, herbal or homeopathic preparation within 7 days or 5 half-lives prior to study drug administration, as determined by the Investigator. Hormone replacement therapy and hormonal is permissible throughout the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    PIPE-791

    Drug: PIPE-791

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Single and multiple ascending oral doses of PIPE-791 tablets.

  • DrugPlacebo

    Single and multiple ascending oral doses of matching placebo tablets.

06

What researchers measure

Primary outcomes

  1. Safety: Treatment-Emergent Adverse Events (TEAE)

    Number of participants with TEAEs

    Time frame: Baseline to 14 days post dosing for SAD cohorts and 14 days post dosing for MAD cohorts

Secondary outcomes

  1. Safety: Cardiac repolarization using Fridericia-corrected QT interval (QTcF)

    Change in mean QTcF

    Time frame: Baseline to 14 days post dosing for SAD cohorts and 14 days post dosing for MAD cohorts

  2. Pharmacokinetics (PK): Blood concentration levels of PIPE-791

    Time frame: Baseline to 14 days post dosing for SAD cohorts and 14 days post dosing for MAD cohorts

  3. Pharmacokinetics: Urine concentration levels of PIPE-791

    Time frame: Baseline on day 1 through day 2 for SAD cohorts and from baseline on day 1 through day 7 for MAD cohorts

07

Study locations

1 site
  • Worldwide Clinical Trials
    San Antonio, Texas 78217, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in Feb 2024, 7 months.

Of 39 industry-sponsored phase 1 interventional studies under Multiple Sclerosis, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 32. This study's 7 months is below that.

Counting every sponsor, half of 92 studies reached it within 30 months; a quarter within 9 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2023
First posted
Aug 9, 2023
StartActual
Jun 26, 2023
Primary completionActual
Feb 1, 2024
CompletionActual
Feb 1, 2024
Last update
Feb 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05983939
Lead sponsor
Contineum Therapeutics
Responsible party
Sponsor
First posted
Aug 9, 2023
Start date
Jun 26, 2023
Primary completion
Feb 1, 2024
Completion
Feb 1, 2024
Last update
Feb 14, 2024

Study contacts

Stephen Huhn, MD
study director · Pipeline Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PIPE-791

Start the discussion